Nevirapine triple combo results released. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Nevirapine triple combo results released. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

Common Factor. 1995 Apr;(no 10):21. Unique Identifier : AIDSLINE AIDS/95700374

Abstract: Preliminary results of ACTG 241 have been released. This study compared the triple therapy of nevirapine plus ddI and AZT against the double combination of ddI and AZT. Preliminary results show participants taking the triple combination had CD4 counts and CD4 percentages that were roughly equivalent to the baseline values. In contrast, the double combination experienced a 25 percent decline in both values. There were about the same number of deaths and disease progressions in both groups. The clinical benefit of the triple combination is still unclear despite the CD4 counts and the lowering of the amount of viral load.
Keywords: Antiviral Agents/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Clinical Trials CD4 Lymphocyte Count Didanosine/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Drug Therapy, Combination Erythema/CHEMICALLY INDUCED Human HIV Infections/*DRUG THERAPY HIV-1/PHYSIOLOGY Pyridines/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE Virus Replication/DRUG EFFECTS Zidovudine/ADVERSE EFFECTS/PHARMACOLOGY/*THERAPEUTIC USE NEWSLETTER ARTICLE

KWDantiviralagents/adverseeffects/pharmacology/KWDtherapeuticuseclinicaltrialscd4lymphocytecountdidanosine/adverseeffects/pharmacology/KWDtherapeuticusedrugtherapy,combinationerythema/chemicallyinducedhumanhivinfections/KWDdrugtherapyhiv-1/physiologypyridines/adverseeffects/pharmacology/KWDtherapeuticusevirusreplication/drugeffectszidovudine/adverseeffects/pharmacology/KWDtherapeuticusenewsletterarticle
951130
M95B0892

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .